Can-Fite expands the out-licensing deal with Ewopharma to include the pancreatic cancer indication
PETACH TIKVA, Israel, January 30, 2024 – Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and oncological diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite. During 2021, Can-Fite … Read more